For instance, we have obtained encouraging results in the course of clinical trials of recombinant immunocytokines constructed on the basis of interleukin-2, anti-cancer humanized antibodies (GD2 disialoganglizid and the epithelial cell adhesion molecule EpCaM), and anti-angiogenesis antibodies (EDB and the extra domain B of fibronectin) for treating melanoma, neuroblastoma, and non-Hodgkin's lymphoma [113, 114] and on the basis of interleukin-2 conjugated with anti-CD20 antibody for treating B-cell malignancy [115]. The gene discussed is IL2; the disease is cancer.